51. Cannabis, Tobacco Use, and COVID-19 Outcomes.
- Author
-
Griffith NB, Baker TB, Heiden BT, Smock N, Pham G, Chen J, Yu J, Reddy J, Lai AM, Hogue E, Bierut LJ, and Chen LS
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Adult, Risk Factors, Aged, Tobacco Use adverse effects, Tobacco Use epidemiology, Tobacco Smoking adverse effects, Tobacco Smoking epidemiology, Marijuana Smoking epidemiology, Marijuana Smoking adverse effects, COVID-19 mortality, COVID-19 epidemiology, Hospitalization statistics & numerical data, SARS-CoV-2, Intensive Care Units statistics & numerical data
- Abstract
Importance: It is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use., Objective: To examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors., Design, Setting, and Participants: This retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US., Exposures: Current cannabis use and tobacco smoking, as documented in the medical encounter., Main Outcomes and Measures: Health outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling., Results: A total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors., Conclusions and Relevance: The findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19-related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.
- Published
- 2024
- Full Text
- View/download PDF